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Abstract: 
 
BACKGROUND: Tumours are made up of a mixed population of different types of cells that 
include normal structures as well as ones associated with the malignancy, and there are multiple 
interactions between the malignant cells and the local microenvironment. These intercellular 
interactions, modulated by the microenvironment, effect tumour progression and represent a 
largely under appreciated therapeutic target. We use observations of primary tumor biology from 
prostate cancer to extrapolate a mathematical model: specifically; it has been observed that in 
prostate cancer three disparate cellular outcomes predominate: (i) the tumour remains well 
differentiated and clinically indolent - in this case the local stromal cells may act to restrain the 
growth of the cancer; (ii) early in its genesis the tumour acquires a highly malignant phenotype, 
growing rapidly and displacing the original stromal population (often referred to as small cell 
prostate cancer) - these less common aggressive tumours are relatively independent  of the local 
microenvironment; and, (iii) the tumour co-opts the local stroma - taking on a classic stromagenic 
phenotype where interactions with the local microenvironment are critical to the cancer growth. 
METHODS: We present an evolutionary game theoretical construct that models the influence of 
tumour-stroma interactions in driving these outcomes. We consider three characteristic and 
distinct cellular populations: stromal cells, tumour cells that are self-reliant in terms of 
microenvironmental factors and tumour cells that depend on the environment for resources but 
can also co-opt stroma.  
RESULTS: Using evolutionary game theory we explore a number of different scenarios that 
elucidate the impact of tumour-stromal interactions on the dynamics of prostate cancer growth 
and progression and how different treatments in the metastatic setting can affect different types of 
tumors. 
CONCLUSIONS: The tumour microenvironment plays a crucial role selecting the traits of the 
tumour cells that will determine prostate cancer progression. Equally important, treatments like 
hormone therapy affect the selection of these cancer phenotypes making it very important to un- 
derstand how they impact prostate cancer’s somatic evolution. 
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Introduction: 
 
When detected early, prostate cancer is a largely curable entity.  Once metastatic, like many 
cancers, cure becomes impossible and one is left with a strategy of chronic disease management.  
Metastatic prostate cancer is initially managed by therapeutic manipulations aimed at ablating 
endogenous androgen production,  a strategy that deprives cells of growth signaling factors.  
Additionally, bisphosphonates or RANK ligand inhibitors disrupt tumor-stroma interactions in 
the bone and are routinely considered as part of the standard of care for metastatic disease1.  
Given a sufficiently long time interval, the emergence of resistance to these strategies is 
inevitable - for example, with hormone therapy resistance, this constitutes a situation called 
castrate resistance.  Once resistance emerges, the disease becomes much more difficult to control, 
symptoms worsen, and the life expectancy drastically shortens. 
 
Carcinogenesis and cancer progression result from evolutionary processes in which the 
interactions between tumour cells, their environment and the surrounding stroma results in 
proliferation of cells from the genetically unstable tumor and, consequently, clinically malignant 
behavior. The concept of microenvironmental changes associated with, and potentially promoting 
expansion of the clones with phenotypes that define cancer dates back to observations by Galen 
in the second century2. Bone marrow derived cells, widely distributed through tissues, play a 
complex range of roles including generating immune and inflammatory responses and 
contributing to fibrotic changes.  
 
The role of specific cell types within this complex hierarchy is becoming better understood. 
Inflammatory cells have been shown to be involved in tumour promotion at many sites including 
the prostate3 4 5. This is likely due to the stimulation of persistent proliferative conditions in the 
presence of a mutagenic environment: some associated factors include the local activation of 
reactive oxygen species6 7. 
 
Well known examples of stromal cells that change in response to the presence of a tumour 
include fibroblasts and osteoclasts, among others. In a series of papers in the 1980s, Schor and 
co-workers demonstrated that fibroblasts adjacent to carcinoma epithelium were fundamentally 
different from normal stroma and that these changes were implicated in neoplastic progression8. 
These malignancy-associated changes only occurred in a subset of the resident fibroblasts9 10.  
References specifically to tumour-associated or carcinoma-associated fibroblasts, myofibroblasts 
and reactive stroma become abundant in literature from the 1970s onward.  
 
The relationship between osteoclasts and tumor cells in metastatic disease in the bone has been of 
recent interest, and much research has gone into understanding signaling cascades including 
many of the matrix metalloproteinases11 which seem to promote a vicious cycle of bone turnover 
and tumor promotion.  Sadly, while these pathways are reasonably well understood, the clinical 
application of our knowledge in this realm has had little impact with the notable exception of 
cladronate in breast cancer - a case where a 'stromal directed' therapy - not an anticancer agent - 
has actually been shown to increase survival12. 
 
We, and others, have shown that carcinoma associated fibroblasts derived from human prostate 
tumours can promote tumourigenesis13 14 15 16. We have also demonstrated that the stromal 
phenotype in a tumour can be used as a basis for patient disease progress prognostication17 18.  
While some of the pathways underlying the ability of cancer stroma to regulate tumourigenesis 
have been elucidated19 20 21, the situation is complex and many interactions remain to be 
explored22, especially with regards to the progression of the carcinoma towards either 
stromagenic (figure \ref{fig:real} left) or stromal independent outcomes (Figure 1 right).  
 
In this paper we introduce an Evolutionary Game Theory (EGT) model that studies the evolution 
of three different cell populations over time: stromal cells, a dependent tumour phenotype capable 
of co-opting stromal cells to support its growth, and an independent tumour phenotype that does 
not require microenvironmental support, be it stromal associated or not. This model is then 
applied to the clinical problem of metastatic prostate cancer. 
 
The Game: 
 
In EGT the behaviour of the players is not assumed to be based on rational payoff maximisation 
but it is thought to be shaped by trial and error - adaptation through natural selection or individual 
learning23. In the context of the evolution of populations there are two game theory concepts to be 
interpreted differently than in traditional game theory. First, a strategy is not a deliberate course 
of action but a phenotypic trait. The payoff is Darwinian fitness, that is more average 
reproductive success. Secondly, the players compete or cooperate to become a larger share of the 
population24.  
 
Genetic and epigenetic changes can transform the cells in a co-operating healthy tissue 
ecosystem.  One change is to produce individualistic tumour cells that compete for space and 
resources25 26 27 and which can attract support from other cell types, for example by replicating 
developmental scenarios where cell growth is a normal outcome. If we consider a tumour as an 
ecosystem, it is possible to use tools from ecology, such as EGT, to study the evolution of the 
different cellular populations.  EGT has been used to explore various aspects of glioma 
progression28 29,  the influence of the tumour-host interface in colorectal carcinogenesis30, the role 
of phenotypic variability in multiple myeloma31 and the evolution of a number of phenotypic 
traits such as motility and invasion32 33 or microenvironmental independence34. 
 
As in our previous work34, the model assumes a tumour with two different epithelial phenotypes: 
tumour cells that depend on the microenvironment for survival (D) and those that are independent 
of the microenvironment (I). Table 1 shows the payoffs for each cell type when interacting with 
others. A further assumption is that no other phenotypes are relevant in the context of the game 
and that spatial considerations will not affect the outcome35. The payoffs in EGT represent the 
fitness change resulting from the interaction - a positive change represents an increase in the 
long-term growth rate of the cell. The payoff values are normalised in the range [0:1] so 1 
represents the maximum fitness for any given phenotype. 
 
Table 1. 
 
The I cells produce their own growth factors (e.g. testosterone) and space (e.g. by degradation of 
the extra cellular matrix) and thus are considered to have a relatively constant fitness (1 - γ), 
where γ represents the fitness cost for I cells to be independent, instead of committing those 
resources to faster proliferation.  The D cells rely on their microenvironment for survival and 
growth at a fitness cost (β) that represents, among other things, the scarcity of resources and 
space. A nutrient deprived microenvironment would then be characterised by a higher value of β. 
Since I cells produce space and shareable growth factors, this model assumes that D cells derive a 
fitness advantage from their interactions with I cells represented by the variable ρ. On the other 
hand, D cells interacting with other D cells will have a harder time sharing resources with equally 
dependent cells and thus are assumed to have double the cost 2β for relying on the 
microenvironment for survival and growth and thus have a fitness of 1-2β. 
 
We further consider a stromal population (S) that can interact with the tumour. The stromal 
compartment is thought to be complicit in tumour progression and represents a potential target for 
new therapies36 as well as possibly an underrecognized one for current therapies such as androgen 
ablation and bisphosphonates.  Stromal cells retain  an ability to undergo rapid proliferation but 
normally are relatively growth quiescent with low rates of proliferation and death. For this reason 
the fitness benefit derived by stromal cells from the interactions with tumour cells is assumed to 
be zero. However, under certain circumstances, stromal cells are susceptible to being co-opted by 
certain tumour phenotypes (much like carcinoma associated fibroblasts). In this situation, stromal 
and tumour cells produce factors that stimulate each other's growth in a mutualistic fashion. For 
the EGT model this is represented by the variable α in the payoff table. A low α represents 
tumours in which the stroma cannot be co-opted. 
 
If pIt is the proportion of I cells at a given time t and pDt the proportion of D cells then the 
absolute fitness of each cell population (W(S), W(I), W(D)) will be given by the following 
expressions: 
 
W(S) = pDt α,       (1.1) 
 
W(I) = 1 - ρ,       (1.2) 
 
W(D)  = (1 - pIt - pDt)(1 - β + α) + pIt(1 - β + ρ) + pDt(1 - 2β) + 
 1 - β + α + pIt(ρ - α) - pDt(β + α).   (1.3) 
 
The average fitness 
€ 
W  of the population is given by: 
 
  
€ 
W  = (1 - pIt - pDt)W(S) + pItW(I) + pDtW(D).   (1.4) 
 
From these expressions it is possible to derive the discrete replicator equations that describe, 
using the absolute fitness of each of the populations, how they change over time23. The proportion 
of a cellular population in the model at a given time t will depend not only on its own fitness (W) 
but also on the fitness of the other cell populations. If the fitness of a phenotype X, W(X) is 
higher than the average fitness of all the phenotypes combined <W> then the proportion of that 
phenotype will increase during the next time step, for as long as the reasons that keep the 
phenotype relatively fit remain. The replicator equations are: 
 
pIt + 1 = pIt
€ 
W (I)
W ,      
(1.5) 
 
pDt + 1 = pDt
€ 
W (D)
W .      
(1.6) 
 
Results: 
 
One may apply the replicator equations described in the previous section to study the temporal 
evolution of the different populations in a number of scenarios. These scenarios are characterised 
by the 4 variables of the model: α, the mutual benefit between D cells and co-opted stroma, ρ, the 
benefit that D cells derive from coexisting with I cells (which can produce growth factors and 
space), β, the fitness cost of relying on a potentially unfriendly microenvironment (e.g. scarce 
resources or susceptibility to environmental apoptotic signals) and γ, the cost that I cells have to 
incur in order to become independent from the microenvironment.  
 
We considered three scenarios describing nutrient rich, neutral and poor environments (assigned 
as three values of the fitness cost of dependence, β = 0.2, 0.5 and 0.8).  In each case, the replicator 
equation was iterated 20 times from an initial condition assuming that both tumour populations 
represented a very small proportion, each 1x10-4 of the population, with the rest being stromal 
cells (S). Different initial conditions yield similar results although the time required to reach 
equilibrium depends on the proportion of tumour cells in the population. We chose 20 time steps 
as it appears to be sufficient for most simulations to reach stability. 
 
The first row in Figure 1.2 shows the outcomes from three scenarios characterised by different 
costs of dependence on the microenvironment with a baseline I phenotype cost set to γ = 0.2. 
When the microenvironment is rich in resources (β = 0.2), the main outcomes are either 
coexistence of tumour phenotypes or, when α or ρ is high (increasing the fitness of the D 
population), coexistence of the three phenotypes.  The second row shows the outcomes from three 
scenarios characterised by different costs of relying on the microenvironment with an I phenotype 
with γ = 0.5.  When the microenvironment is rich in resources the main outcomes are either 
dominance of D phenotypes or, when γ is sufficiently high, coexistence of D and S.  
 
When resources are neither scarce nor plentiful the main outcomes are coexistence of I and D if α 
is sufficiently small or coexistence of I and stroma if α is high enough. Interestingly for some 
values of α (from medium to intermediate-high), the outcome tends to be coexistence of the three 
phenotypes. For environments poor in resources (β = 0.8) the main outcomes are driven by ρ, 
with low values of ρ (benefit for D cells coexisting with I cells) leading to dominance of I 
phenotypes and higher ones leading to coexistence of both tumour phenotypes.  
 
The third row shows the outcomes from three scenarios characterised by different costs of relying 
on the microenvironment with an I phenotype with γ = 0.8, representing a relatively unfit I 
population.  When the microenvironment is rich in resources the main outcomes are either 
dominance of D phenotypes or, when α is sufficiently high, coexistence of D and S. When 
resources are neither scarce nor plentiful the main outcomes are coexistence of I and D if α is 
sufficiently small or coexistence of D and S if α is high enough. Perhaps the most dynamically 
interesting and biologically relevant simulation is when the microenvironment is poor in 
resources (β = 0.8) and the cost of being independent is high (γ = 0.8) as shown in the bottom 
right corner of Figure 2. 
 
If both ρ and α are low then the tumour will be dominated by I phenotypes. If α is  0.5 or below, a 
sufficiently high value of ρ leads to tumours that contain both I and D cells. When α is higher 
than 0.5 the cooperation between stroma and D results in the extinction of I cells. Coexistence 
between the three phenotypes occurs when ρ is high (which helps the D cells) and α is below 0.5 
but not too low (over 0.3) which promotes cooperation between D and stromal cells without 
driving I cells to extinction. 
 
As the emergence of tumours dominated by stroma (stromagenic) versus those independent of 
stroma is of greatest interest, the dynamics of these outcomes were explored in more detail.  
Figure 3 shows the time evolution of the replicator equation for two specific examples. The figure 
shows how small changes in the fitness of I (as determined by γ) or D phenotypes (as determined 
by β, ρ and α) could result in large changes in the population dynamics leading to fundamentally 
different outcomes. Left panel: a sufficiently high value of α and low value of ρ means that D 
cells derive a much higher benefit from their cooperation with stromal cells than from their 
interactions with I cells. Given the low general fitness of the I cells (with γ = 0.8) it is not 
surprising that they quickly become extinct as the advantage of cooperation sustains and 
promotes D and S cells in the tumour. The right panel in the same figure shows a slightly fitter I 
phenotype (with γ = 0.75 instead of 0.8), the I population manages to sustain growth and, as it 
becomes an increasingly larger part of the tumour population, disrupts the already initiated 
cooperation between D and S cells, resulting in the extinction of the stromal population and a D 
population that represents a smaller part of the tumour compared with the previous example. 
 
In reality, changes in the microenvironment can occur during tumor progression.  Figure 4  
illustrates how a dynamic microenvironment can disrupt the outcome and drive the tumour from 
stromagenic to stromal independent or viceversa.  The replicator equation equations are initially 
iterated to form a stromagenic tumour (as in the left panel of figure 3) then after 20 iterations the 
microenvironment is altered such that it becomes harsher (i.e. increase β from 0.8 to 0.9). This 
results in a destabilisation of the cooperation between the D and S populations and a state 
transition to one exhibiting dominance of the I subpopulation. 
 
Therapeutic Implications: 
 
From the results presented in Figure 3 it is clear that small changes in the fitness of the I 
phenotypes (given all other parameters are equal) can lead to a large scale changes in populations 
- even causing phase transitions from stromal independence to a stromagenic tumours. While both 
of these tumor types are eventually lethal, it has been postulated that the stromagenic tumours 
have a longer natural history1736 
\cite{Ayala:2003zh}37.  Further, because of the biological aspects of the different phenotypes, 
they are likely sensitive to different types of therapy.  For example, manipulation of a biological 
pathway (such as mTOR) would differentially penalise cells which depend more upon intrinsic 
signalling (I), while manipulation of stromal cells or tumour-stroma signalling (such as hormonal 
therapy for localised disease or a bisphosphonate for bony metastatic disease) would 
preferentially effect the D cells.  Additionally, as the steady states depend not only on the 
parameters (which can be manipulated by therapy) but also on the relative populations, the timing 
of therapy can drastically change the results. 
 
An exploration of a putative biological therapeutic agent with different timing strategies is 
represented in Figure 5.  In the case of this simulated biological therapy (possibily representing an 
mTOR inhibitor - which preferentially penalises the I population), the end effect of the therapy is 
strongly influenced by the time of initiation - when initiated early (when there is still competition 
between I and D), it drastically alters the outcome of the game, while late application (after I has 
already dominated) only causes a small shift.  This result can be seen as an application of the 
\emph{kairos principle} and speaks to the importance of choosing the right therapy at the right 
time.  Testing this same concept in a more 'stromal targetted' therapy (e.g. hormonal 
manipulation) did not produce significant differences, suggesting that a short delay in onset is of 
less importance in this therapeutic strategy.  This result does not suggest that early versus late 
hormone therapy is meaningless - in fact it has been shown that early hormone therapy can 
slightly increase overall survival - but instead that the timing will not effect the overall outcome 
of the game. 
 
Testing a different therapeutic strategy, the duration of 'stromal directed' therapy is shown in 
Figure 6.  Here, we hypothesize that application of such a therapy would primarily effect the 
benefit D cells receive from the interatcion with S cells (i.e. α will be reduced).  This results in a 
shift in the opposite direction from the prior therapy - from D to I.  Further, we see that the 
duration of therapy strongly effects the end result of the game.  The final result (Figure 6c) 
recapitulates the clinical reality of evolution of resistance to hormonal therapy (e.g. castrate 
resistant prostate cancer). 
 
Discussion: 
 
Although many nascent prostate tumours never become life threatening, those that do can use two 
different and distinct routes: either becoming microenvironmentally independent (representing a 
small cell prostate cancer type scenario) or by co-opting certain stromal cells in order to sustain 
tumour progression (as happens in bony metastatic disease). We present a simple model that 
abstracts key aspects of prostate cancer evolutionary dynamics including progression towards 
lethal outcomes that can be either stromagenic (resulting from mutualistic interactions between 
the tumour and certain stromal cells) or stromal independent. These outcomes, reflecting 
evolutionary changes of the genetically unstable, heterogenous tumor cell population, are 
influenced by the interactions both between the different populations (I, S and D) and with their 
microenvironment. Primary tumours are likely to contain areas that are stromagenic as well as 
other areas that are stromal independent which would make application of the therapeutical 
message of this model less relevant. On the other hand secondary sites are thought to represent 
clonal populations originating from a specific (either stromagenic or stromal independent) area of 
the primary tumour38, therefore extrapolating to the metastatic situation is more appropriate. 
 
We have previously demonstrated34 dominance of D phenotypes happens naturally in a 
microenvironment rich in resources whereas resource-poor microenvironments tend to select for I 
cells. These results are further validated by this model: regardless of the absolute fitness of the I 
phenotype (as given by γ), an increase in the proportion of I cells is observed as the 
microenvironment becomes resource-poor (as given by β, right column of Figure 2). Stroma and 
its interactions with the tumour have a tremendous impact on the phenotypic composition of the 
tumour. In those cases in which α is sufficiently high, denoting stroma which can be supported by 
the tumour, the cooperation between D and S can push the I population towards extinction (see 
Figure 3 left panel). Conversely, this can be described as tumor cells which are particularly 
effective at eliciting stomal support - the key is the interactive process, not so much the cell's 
absolute behavior.   
 
On the other hand, when ρ is sufficiently high, the ensuing mutualistic relationship between D 
and I can lead to dominance of the tumour phenotypes at the expense of S, even when the D cells 
can derive some benefit from their interactions with the stroma (see figure \ref{fig:example} right 
panel). The least frequent of the outcomes, coexistence of the three phenotypes, depends on 
values of α being high enough to promote the collaboration between D and stromal cells but not 
so high that I cells are driven to extinction. Higher values of ρ promote polyclonal tumours as 
they allow D cells to coexist with I cells. Thus, those tumours in which the D cells can benefit 
from the factors produced by I cells and still cooperate with the stroma are more likely to sustain 
the three phenotypes in an evolutionarily stable strategy. 
 
To combat the emergence of castrate resistance (and side effects) in the treatment of metastatic 
prostate cancer, many physicians have adopted non-standard dosing schedules for their androgen 
ablation therapies.  A recent study suggested that either using the patient's measured testosterone 
levels as a guide, or using an intermittent schedule as opposed to constant dosing (a calendar 
schedule) slowed the onset of castrate resistance39.  While this study has shown that alternative 
schedules can provide benefit, there is, as of yet, no standard of care for this.  To explore this 
question, simulations were run with differing times of initiation and duration of 'stromal directed' 
therapy.  The results of the game given different durations of 'stromal directed' therapy show 
significant, fundamental differences in outcome with differing schedules.  Initiation with short 
duration of treatment (Figure 6a) results in no appreciable change in the game.  Initiation for long 
duration (Figure 6c), as expected, shows the evolution of castrate resistance and a phase transition 
to a new steady state dominated by I cells which will then be insensitive to further manipulation 
with this therapy, requiring a strategy change.  There is, however, an optimal duration (Figure 6b) 
where the D cells are reduced without an irreversible increase in the I cells.  When the therapy is 
taken off, the levels begin to return to the original D dominated steady state; a situation where 
'stromal directed' therapy will work again. 
 
These results, taken together, suggest that different therapies are likely of different value to the 
two major tumour types:  D tumours are likely best treated with stromal manipulation (e.g. 
hormonal therapy) while I tumours would be better treated initially with a biologic agent such as 
an mTOR inhibitor. 
 
Regardless of timing and schedule, the emergence of castrate resistance is largely unavoidable 
given a long enough time frame, and these results suggest that when this emergency does occur, a 
treatment strategy change is in order.  These sentiments are echoed in the recent literature which 
suggests that the addition of mTOR inhibitors to hormone therapy after the onset of castrate 
resistance40 could hold promise. 
 
Conclusions: 
 
The results presented here highlight the importance of understanding tumour-stroma interactions 
in driving not only tumour outcomes (whether malignant or not) but also their impact on 
potentially new therapeutic approaches. A key assumption made here is that the biology of 
metastatic sites is related to the original biology of the primary tumor.  While this assumption 
carries with it many other assumptions, it is one that underlies the majority of clinical decision-
making and biological extrapolation in prostate cancer.   
 
In the clinical paradigm of metastatic prostate cancer, which has recently been muddied with 
many new agents coming to the arena, it has become ever more important to develop rational 
strategies with which to test new sequence and timing regimens.  For example, it may be that the 
time honored standard of hormonal manipulation until failure is no longer the best strategy - but 
how can we rationally integrate these new therapies?  While our results provide a theoretical 
framework with which to understand clinical observations they do not yet provide us with the 
ability to make strong recommendations for timing and duration of therapy (limited by the 
arbitrary nature of the time variable in this model), however, this model has already generated 
testable hypotheses and with direct experimental parameterization and validation could lead to 
specific therapeutic strategies. 
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